Cost-Effectiveness Analysis of Continuous-Flow Left Ventricular Assist Devices as Destination Therapy

Abstract

The cost-effectiveness associated with continuous-flow LVADs for destination therapy has improved significantly relative to the pulsatile flow devices. This change is explained by significant improvements in survival and functional status and reduction in implantation costs.